3NG5 image
Entry Detail
PDB ID:
3NG5
Title:
Crystal Structure of V30M transthyretin complexed with (-)-epigallocatechin gallate (EGCG)
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2010-06-11
Release Date:
2010-07-07
Method Details:
Experimental Method:
Resolution:
1.70 Å
R-Value Free:
0.22
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Transthyretin
Mutations:V30M
Chain IDs:A, B
Chain Length:127
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Crystal structure of green tea polyphenol(-)-epigallocatechin gallate (EGCG)-transthyretin complex reveals novel binding site distinct from thyroxine binding site
Biochemistry ? ? ? (2010)
PMID: 20565072 DOI: 10.1021/bi1004409

Abstact

Amyloid fibril formation is associated with protein misfolding disorders, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's diseases. Familial amyloid polyneuropathy (FAP) is a hereditary disease caused by a point mutation of the human plasma protein, transthyretin (TTR), which binds and transports thyroxine (T(4)). TTR variants contribute to the pathogenesis of amyloidosis by forming amyloid fibrils in the extracellular environment. A recent report showed that epigallocatechin 3-gallate (EGCG), the major polyphenol component of green tea, binds to TTR and suppresses TTR amyloid fibril formation. However, structural analysis of EGCG binding to TTR has not yet been conducted. Here we first investigated the crystal structure of the EGCG-V30M TTR complex and found novel binding sites distinct from the thyroxine binding site, suggesting that EGCG has a mode of action different from those of previous chemical compounds that were shown to bind and stabilize the TTR tetramer structure. Furthermore, EGCG induced the oligomerization and monomer suppression in the cellular system of clinically reported TTR variants. Taken together, these findings suggest the possibility that EGCG may be a candidate compound for FAP therapy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures